Prolacta
City Of Industry, US · Founded 1999 · Delaware corporation · 321 employees on LinkedIn · 5 known investors
Find your way into Prolacta
Sign up to see every warm intro you have to Prolacta
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Prolacta team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units. The company's products are used to support nutrition and reduce complications in extremely premature infants globally.
Founders & leadership

Board



Investors · 5
How we know: Aisling Capital's portfolio page · Not right? Tell us
How we know: Essex Woodlands Healthcare Partners's portfolio page · Not right? Tell us
How we know: board seat on SEC Form D · funding news · Not right? Tell us
Reported raises · per SEC filings
Form D private placements$43.9M disclosed across 2 rounds · 2016–2018
▶$8.9MraisedMay 2018 · 11 investors · BiotechnologyRule 506(b)
- John ShieldsExecutive Officer
- David BrailerDirector
- Mark HannonExecutive Officer
- Victoria NiklasExecutive Officer
- Ernie StrapazonDirector
- Frank FosterDirector
- John Bacich Jr.Director
- David DreyerExecutive Officer
- Vincent GasparExecutive Officer
- Alan KofskyExecutive Officer
- Martin SutterDirector
- Scott EakerExecutive Officer
- Scott ElsterExecutive Officer, Director
- Joseph FournellExecutive Officer
- Martin LeeExecutive Officer
- Dan JanneyDirector
- Sally CrawfordDirector
- Alyson FullerExecutive Officer
- Offering amount
- $8.9M
- Amount sold
- $8.9M
- First sale
- May 2018
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$35MraisedDec 2016 · 4 investors · BiotechnologyRule 506(b)
- Scott ElsterExecutive Officer, Director
- Frank FosterDirector
- Martin SutterDirector
- John Bacich, Jr.Director
- Ernie StrapazonDirector
- Ned BrownDirector
- Sally CrawfordDirector
- David BrailerDirector
- Dan JanneyDirector
- John M. ShieldsExecutive Officer
- Offering amount
- $35M
- Amount sold
- $35M
- First sale
- Nov 2016
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Related companies · 1
Companies working in the same space as Prolacta.
In the news
Frequently asked questions
- What does Prolacta do?
- Prolacta Bioscience manufactures 100% human milk-based nutritional products and fortifiers for premature and critically ill infants in hospital neonatal intensive care units. The company's products are used to support nutrition and reduce complications in extremely premature infants globally.
- Who are Prolacta's investors?
- Prolacta's investors include Aisling Capital, Essex Woodlands Healthcare Partners, Frontier Venture Capital, PROOF, Alta Partners.
- How much funding has Prolacta raised?
- Prolacta has disclosed $43.9M raised across 2 rounds.
- Where is Prolacta headquartered?
- Prolacta is headquartered in City Of Industry, US.



